ArriVent BioPharma (AVBP) Long-Term Investments (2024 - 2025)
ArriVent BioPharma's (AVBP) quarterly Long-Term Investments came in at $5.1 million in Q3 2025, down 72.82% quarter-over-quarter from $18.8 million in Q2 2025.
ArriVent BioPharma (AVBP) Long-Term Investments (2024 - 2025) Analysis & Trends
ArriVent BioPharma has disclosed Long-Term Investments across 2 years of filings, most recently posting $5.1 million for Q3 2025.
- Long-Term Investments for Q3 2025 came in at $5.1 million, changed N/A year-over-year; the trailing twelve-month figure through Sep 2025 was $5.1 million (changed N/A YoY), and the FY2024 annual result was $47.7 million, changed N/A from the prior year.
- Long-Term Investments came in at $5.1 million for Q3 2025 at ArriVent BioPharma, down from $18.8 million in the prior quarter.
- In the past five years, Long-Term Investments ranged from a high of $47.7 million in Q4 2024 to a low of $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 5.17 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 5.75 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | ArriVent BioPharma | 1.37 Bn | 1.37 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 5.11 Mn |
| Jun 30, 2025 | 18.79 Mn |
| Mar 31, 2025 | 29.41 Mn |
| Dec 31, 2024 | 47.68 Mn |